Dr. Neda Hashemi Sadraei
Claim this profileUniversity of New Mexico Cancer Center
Studies Skin Cancer
Studies Cancer
14 reported clinical trials
40 drugs studied
Area of expertise
1Skin Cancer
Stage IV
Stage III
2Cancer
Stage IV
Affiliated Hospitals
Clinical Trials Neda Hashemi Sadraei is currently running
Hormone + Radiation Therapy
for Prostate Cancer
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
Recruiting2 awards Phase 36 criteria
Pembrolizumab
for Bladder Cancer
Subjects with cT2-T3N0M0 urothelial cancer of the bladder will be enrolled. After completing two cycles of pembrolizumab, subjects will undergo a restaging MRI of the abdomen and pelvis with a standard acquisition protocol (as outlined in the protocol) as well as CT chest. A CT of the abdomen and pelvis may be performed if there are contraindications to MRI. Patients will also undergo a restaging cystoscopy and biopsies/TURBT as outlined in the protocol. Patients achieving a clinical complete response to treatment (defined in the protocol) will proceed with "maintenance" single agent pembrolizumab followed by surveillance. All other patients will proceed with standard of care local therapy as per their treating physicians followed by "adjuvant" pembrolizumab.
Recruiting1 award Phase 28 criteria
More about Neda Hashemi Sadraei
Clinical Trial Related4 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Neda Hashemi Sadraei has experience with
- Nivolumab
- Pembrolizumab
- Radiation Therapy
- Avelumab
- Durvalumab
- Ipilimumab
Breakdown of trials Neda Hashemi Sadraei has run
Skin Cancer
Cancer
Bladder Cancer
Prostate Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Neda Hashemi Sadraei specialize in?
Neda Hashemi Sadraei focuses on Skin Cancer and Cancer. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is Neda Hashemi Sadraei currently recruiting for clinical trials?
Yes, Neda Hashemi Sadraei is currently recruiting for 6 clinical trials in Albuquerque New Mexico. If you're interested in participating, you should apply.
Are there any treatments that Neda Hashemi Sadraei has studied deeply?
Yes, Neda Hashemi Sadraei has studied treatments such as Nivolumab, Pembrolizumab, Radiation Therapy.
What is the best way to schedule an appointment with Neda Hashemi Sadraei?
Apply for one of the trials that Neda Hashemi Sadraei is conducting.
What is the office address of Neda Hashemi Sadraei?
The office of Neda Hashemi Sadraei is located at: University of New Mexico Cancer Center, Albuquerque, New Mexico 87106 United States. This is the address for their practice at the University of New Mexico Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.